Numbers of families/cases studied from each of the five series and the frequency of each molecular change
| Series (No of cancers) | K-ras mutation | APC LOH | 18q LOH | MSI | β-Catenin mutation | β-Catenin IHC | p53 IHC | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Numbers of cancers with that molecular change as proportion of total cancers of that type studied (and percentages) are shown. Pairwise and overall comparisons of each molecular variable between series showed no significantly different frequencies, except as detailed in the text. | ||||||||||||||
| FCC, family cancer clinic; HNPCC, hereditary non-polyposis colon cancer; IHC, immunohistochemistry; LOH, loss of heterozygosity; MAP, MYH associated polyposis; MSI, microsatellite instability; N/D, not determined. | ||||||||||||||
| HNPCC (43) | 11/39 (28%) | 10/28 (36%) | 9/25 (36%) | 43/43 (100%) | 5/34 (15%) | 17/37 (46%) | 23/32 (72%) | |||||||
| MAP (17) | 9/14 (64%) | 0/13 (0%) | 7/14 (50%) | 0/17 (0%) | 0/16 (0%) | 12/17 (71%) | 8/15 (53%) | |||||||
| Multiads (49) | 11/41 (27%) | 18/31 (58%) | 15/28 (54%) | 5/49 (10%) | N/D | 27/45 (60%) | 28/39 (72%) | |||||||
| FCC (150) | 34/117 (29%) | 54/112 (48%) | 47/86 (55%) | 18/139 (13%) | 0/54 (0%) | 50/104 (48%) | 50/73 (68%) | |||||||
| Unselected (100) | 30/89 (34%) | 38/69 (55%) | 42/94 (45%) | 10/100 (10%) | 1/100 (1%) | N/D | N/D | |||||||